BioSpace News Archive

NOXXON ends the use of variable rate equity financing with Yorkville

Overall response rate at 28 days of 60%, complete response rate of 50%

Clinigen Group plc announces that Professor Alan Boyd has been appointed as a Non-Executive Director with immediate effect.

Positive outcomes from second Phase 1 trial with intranasal betahistine

Highlights potential role of both complement and leukotriene pathways in a therapeutic mouse model of rheumatoid arthritis (RA)

The U.S. Department of Commerce announced today that the 2018 Malcolm Baldrige National Quality Award will be given to two educational institutions, an organ donor group, a hospital and a project management firm.

Thomas Eldered, CEO and co-founder of Recipharm AB, has informed the Company that he has sold 1,559,125 Class B shares in Recipharm, representing approximately 12.7% of his total shareholding in the Company, to a Swedish institutional investor.

Exscientia, the company leading the use of Artificial Intelligence (AI) in drug discovery, announces that is has acquired the biophysics specialists, Kinetic Discovery, a private UK company. The acquisition builds up Exscientia’s capabilities for tackling novel drug targets to create first-in-class drug candidates by seeding its algorithms with data generated through the use of fragment screening and structural biology.

Arix Bioscience plc is pleased to note that Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, has announced positive results from the Phase 1 clinical trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF).

The highly successful twenty-fourth annual BIO-Europe(R) international partnering conference wrapped up in Copenhagen, Denmark, last week with a record-breaking 4,200+ attendees from the life sciences who engaged in over 26,000 one-to-one partnering meetings vying for 3,145 licensing opportunities on offer.